By Sabela Ojea
Corcept Therapeutics drug Korlym, which treats hypercortisolism and difficult-to-control type 2 diabetes, met its primary endpoint in the treatment phase of CATALYST, a randomized, double-blind, placebo-controlled study.
The pharmaceutical company on Thursday said that the safety profile of Korlym in the study was consistent with the medication's label and no new side effects or adverse events were identified.
Complete results from the study will be presented at a medical conference next year, the company said.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
December 12, 2024 17:47 ET (22:47 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。